Pegcetacoplan 1.08g/20ml solution for infusion vials
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Pegcetacoplan
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Pegcetacoplan
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Pegcetacoplan on the MHRA register
Aspaveli 1080mg/20ml solution for infusion vials
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Clinical guidelines and formulary information
British National Formulary
Pegcetacoplan
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(3)
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)
Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
8.0 days
Mechanism
PNH is due to a mutation in the phosphatidylinositol N-acetylglucosaminyltransferase subunit A (PIGA) gene.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
4.5-6.0 days
[L34095]
Patients reach steady state pharmacokinetics after 6-8 weeks.
[A235000]
Half-life
8.0 days
[L34095]
Volume of distribution
3.9 L
[L34095]
Metabolism
[L34095]
Elimination
Clearance
0.37 L
[L34095]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021.[L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354]
[L34095]
It is also indicated to treat geographic atrophy (GA) secondary to age-related macular degeneration.
[L45354]
Pegcetacoplan is also used to treat adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria.
[L53708]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 359 interactions
[L34095]
In the case of an overdose, patients should be treated with symptomatic and supportive measures.
The alternative complement system pathway is spontaneously activated due to the absence of CD55, leading to activation of a C3 convertase that that cleaves C3 into C3a and C3b.[A234975] C3b binds to factor B, which is cleaved by factor D into the smaller Ba and larger Bb.[A234980] The resulting C3bBb can bind to other C3 proteins, leading to a positive feedback loop of complement activation.[A234980] C3b proteins can also bind directly to a target cell, marking it as a target for phagocytosis.[A234995] CD55, also known as decay-accelerating factor (DAF) disrupts the formation of C3bBb, preventing spontaneous activation of the alternative complement pathway.[A234980]
C3b cleaves C5 into C5a and C5b.[A234975] C5b combines with complement proteins C6, C7, C8, and C9 to form the membrane attack complex (MAC).[A234980] The MAC is a pore formed in the cell by 16 C9 proteins associated with C5b, C6, C7, and C8.[A234990] Formation of pores destroys the cell membrane leading to cell death.[A234990] CD59 disrupts the formation of the MAC, preventing hemolysis.[A234975]
In patients with PNH, extravascular hemolysis is mediated by C3b marking red blood cells for phagocytosis, and intravascular hemolysis is mediated by the MAC.[A235000][L34095] Pegcetacoplan binds to C3 and C3b, reducing cleavage and activation of complement pathways, reducing both extravascular and intravascular hemolysis.[L34095]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L34095]
Patients reach steady state pharmacokinetics after 6-8 weeks.
[A235000]
[L34095]
[L34095]
[L34095]
[L44371]
[L34095]
Proteins and enzymes this drug interacts with in the body
ATC S01XA31
ATC L04AJ03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Pegcetacoplan
Patent information
15 active patents
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: